On June 9, The Ottawa Hospital announced an exciting breakthrough treatment for some MS patients. The clinical trial , supported by our autologous stem cell program, was just published in The Lancet and has received world-wide media attention.

Led by The Ottawa Hospital, a groundbreaking trial called Cellular Immunotherapy for Septic Shock is testing the idea that mesenchymal stem cells may be able to help control the body’s immune system to reduce injury and promote healing, while improving its ability to fight infection.